<DOC>
	<DOCNO>NCT01541852</DOCNO>
	<brief_summary>The main purpose study determine effect Losmapimod blood vessel patient Chronic Obstructive Pulmonary Disease ( COPD ) . Although COPD lung disease , also associate increase risk cardiovascular disease ( e.g . heart attack stroke ) . The investigator believe result inflammation within body , damage line ( endothelium ) wall blood vessel . These change promote development fatty deposit within wall artery ( atherosclerosis ) rupture block artery cause damage .</brief_summary>
	<brief_title>Losmapimod Chronic Obstructive Pulmonary Disease Patients Stratified Fibrinogen .</brief_title>
	<detailed_description>The study aim enrol sufficient COPD subject ( stratified fibrinogen level ) 60 patient complete study . Study patient 50 % chance receive either Losmapimod Placebo . Patients expect attend 12 visit , 24 week period . The visit consist initial screen visit , 2 pre-dose image visit include PET-CT scan optional MRI scan . The next 7 visit ( 2-4 weekly interval ) involve blood test safety evaluation . A number procedures include heart tracing ( ECGs ) , non-invasive vascular measurement lung function test start end study . Repeat image PET-CT MRI perform end study follow-up visit . The purpose study see study medication beneficial effect vascular function structure . It envisage trial help define evolutionary biomarkers focus help COPD patient future .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>1 . Male female patient 50 85 year age inclusive screening , body weight ≥ 45 kg BMI ≤35 kg/m2 . 2 . Patients clinical diagnosis COPD GOLD Stages 1 , 2 , 3 4 , GOLDU . 3 . Patient FEV1/FVC &lt; 0.7 postbronchodilator . 4 . Patient smoker exsmoker smoke history least 10 pack year ( 1 pack year = 20 cigarette smoke per day 1 year equivalent ) . 5 . Baseline fibrinogen value &gt; 2.8 g/L ( Klauss method ) 6 . ALT &lt; 2xULN screening ; alkaline phosphatase bilirubin &gt; 1.5xULN screening ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . 7 . Patients must QTc &lt; 450 msec screening ( V1 ) ECG ( use average value triplicate ECGs ) . For patient complete Right bundle branch block , QTc must &lt; 480msec Screening V1 ECG . Patients ECG finding exclude warranted discretion CI/PI . QTc read QTcF . 8 . Patients fulfil local imaging centre requirement enrol . The presence follow preclude patient inclusion : 1 . Inability opinion PI provide Informed Consent . 2 . A cardiovascular event last 6 month ( i.e . acute coronary syndrome , unstable angina , CABG , PCI , stroke , MI , carotid endarterectomy ) . 3 . Patients daunorubicin , doxorubicin , topotecan , mitoxantrone . 4 . Previous lung reduction surgery . 5 . Patients know clinically significant pulmonary diagnosis inflammation think play role include diagnosis bronchiectasis , sarcoidosis , lung fibrosis , interstitial lung disease , α1antitrypsin deficiency . 6 . A positive pretrial Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . 7 . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . 8 . Patients know chronic infection HIV know active tuberculosis . 9 . Patients rheumatoid arthritis , connective tissue disorder condition know associate active chronic inflammation ( e.g . Inflammatory Bowel Disease ) . 10 . Insulin control Type 1 Type 2 diabetic . 11 . Diabetics oral hypoglycaemics/diet HbA1c ( DCCT ) &gt; 8 % ( OR HbA1c ( IFCC ) &gt; 64 mmol/mol ) , screen . [ note : fasting glucose check first FDGPET/CT scan , glucose &gt; 11mmol/L visit , patient exclude trial ] 12 . Participation previous research trial last 3 year involve exposure significant ionising radiation ( i.e . cumulative research radiation dose &gt; 5 mSv ) 13 . History malignancy within past 5 year ( exception localize carcinoma skin resect cure ) . 14 . Previous exposure Losmapimod . 15 . Patients donate 500 mL blood within 2 month prior trial medication administration , Visit 3 ( Day 1 ) . 16 . Participation clinical trial patient receive drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose trial medication , Visit 3 ( Day 1 ) . 17 . History alcohol/drug abuse dependence within 6 month trial , Screening Visit 1 ( Day 45 14 ) . 18 . Women childbearing potential exclude trial . 19 . Any medical history clinically relevant abnormality deem principal investigator and/or medical monitor make patient ineligible inclusion safety concern . 20 . Use systemic corticosteroid ( oral IV ) 4 week prior Visit 2 ( Day 14 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Vascular Inflammation</keyword>
	<keyword>FDG PET-CT</keyword>
	<keyword>COPD</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>p38 MAP kinase inhibitor</keyword>
</DOC>